EMA Authorised: Afinitor (everolimus) — Novartis Europharm Limited

View source ↗

Summary

EMA authorised Afinitor (everolimus) for renal cell carcinoma, breast cancer and pancreatic neoplasms. The marketing authorisation holder is Novartis Europharm …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Renal Cell;Breast Neoplasms;Pancreatic Neoplasms. MAH: Novartis Europharm Limited. Decision date: 20/11/2025